Pramiracetam Powder

(No reviews yet) Write a Review


Notice: This product is sold as a nootropic compound. Any usage is based on your own research, please consider all warnings and recommendations before completing purchase. By purchasing this product, you agree to potential risks associated with this particular ingredients and our terms & conditions.

Ingredient List:
 Pramiracetam Powder

Pramiracetam (full chemical name of Diisoprop-yl-(2-oxopyrrolidin-1-yl)acetamide[2] and codename CI-879[3]) is a synthetic racetam.[3] Racetams are synthetic compounds that share a structure called a pyrrolidone nucleus. Many racetams are classified as a nootropic and show promise for improving brain function. Molecule with structural similarities to the parent molecule, Piracetam, and is used for nootropic purposes albeit in lower dosages.[4]

When looking at the animal evidence, otherwise healthy young and old rats seem to experience benefits to long-term memory formation with supplementation of pramiracetam. It appears to be effective when taken acutely (1-2 hours) before cognitive testing, and studies looking at working memory do not note much effects. Human studies support this, but they are limited in statistical power and currently there are no human studies in otherwise healthy youth for the purpose of cognitive enhancement.[1][3]

The mechanisms of pramiracetam are not well known, but it appears to alter EEG activity in all tested rats (young and old) and may be able to enhance high-affinity choline uptake. It is similar to piracetam and other racetams in the sense that its mechanisms seem dependent on the adrenal glands and some peripheral effects, but beyond that the mechanisms have not been further elucidated.[1][5][6]


Study: Diisoprop-yl{2-[2-(2-oxopyrrolidin-1-yl)acetamido]eth-yl}ammonium hydrogen sulfate.[2]
Abstract - The structure of the title compound, C(14)H(28)N(3)O(2) (+)·HSO(4) (-), a nootropic drug (pramiracetam) investigated for cognition-enhancing properties, is closely similar to that of the previously determined acetonitrile solvate, both structures being characterized by the presence of ribbons of hydrogen-bonded ions. The pyrrolidine ring adopts an envelope conformation.[2]

Study: The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task.[3]
Abstract - The effect of the nootropic drug pramiracetam (CI-879) on acquisition of a radial arm maze task was examined in the rat. Two doses of pramiracetam (7.5 mg/kg and 15 mg/kg) were administered daily prior to testing for 7 weeks in a 16-arm radial maze in which nine arms were baited with food. This procedure permitted a distinction between working memory (short-term) and reference memory (long-term). Both doses of pramiracetam significantly improved performance in the reference memory component of the task, but did not significantly affect the working memory component. These data indicate that pramiracetam can enhance some aspects of spatial learning and memory in the rat.[3]

Study: Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.[4]
Abstract - A series of N-[(dialkylamino)alkyl]-2-oxo-1- pyrrolidineacetamides was synthesized. The title compounds reversed electroconvulsive shock (ECS) induced amnesia in mice when administered subsequent to the ECS treatment and were inactive in a general observational test for central nervous system (CNS) activity. Active compounds exhibited an inverted U-shaped dose-response curve. Among the compounds with the broadest dose-response curve, as well as the most potent, were those with the N-[2-[bis(1-methylethyl)amino] ethyl] or 2,6- dimethylpiperidinoethyl residues as amide substituent. The N-(dialkylamino) substituent markedly enhances amnesia-reversal activity, with ethylene providing the optimal chain length. N-[2-[Bis(1-methylethyl)amino]ethyl] -2-oxo-1- pyrrolidineacetamide N-(dialkylamino) substituent was selected for preclinical toxicological evaluation, assigned the investigational number CI-879 and the U.S. adopted name ( USAN ) pramiracetam . Pramiracetam demonstrated a wide margin of safety in animals and was well tolerated in normal human volunteers. It has shown encouraging activity in an open label trial in patients with primary degenerative dementia (PDD or senile dementia of the Alzheimer's type).[4]

Study: Arousal deficit shown in aged rat's quantitative EEG and ameliorative action of pramiracetam compared to piracetam.[5]
Abstract - The basal EEG profile of the aged Fisher-344 rat was consistently different from that of the young rat, showing dominant high voltage slow-wave components. These slow waves were present in both the frontal cerebral cortex and dorsal hippocampus. Absent or greatly attenuated in the aged rat's hippocampal EEG was rhythmic theta activity, which was always dominant in the young awake rat's hippocampus. These EEG differences were clearly apparent only under basal test conditions, i.e., following habituation to the test situation. Pramiracetam sulfate acted strongly to normalize the aged rat's EEG, while the action of piracetam was weak and appeared to undergo tolerance development.[5]

Study: Pharmacologic therapeutic window of pramiracetam demonstrated in behavior, EEG, and single neuron firing rates.[6]
Abstract - Following oral or intravenous administration, a representative cognition activator drug, pramiracetam sulfate, is shown to have a pharmacologic therapeutic window at three different levels of study: learned behavior, gross EEG activity of the frontal cortex and hippocampus, and firing rate of single hippocampal neurons.[6]

Citation & Resources:






Toxicity & Measurement Guidelines


Transfer unit is ~60mg per leveled scoop.


"The racetams possess a very low toxicity and lack serious side effects."[1]

References & Citations:

1. Piracetam and other structurally related nootropics.

Statements & Warnings

These statements have not been evaluated by the Food & Drug Administration. This product is not approved by the FDA. This product is not intended to diagnose, treat, cure or prevent any diseases.

Keep out of the reach of children. Do not take this or any other compound if under the age of 18, pregnant or nursing a baby, or if you have any known or suspected medical conditions and/or taking prescription drug(s) or OTC medication(s). Always consult with a qualified health physician before taking any new compound.

View AllClose